Getinge Reports Strong Second Quarter Driven by High Profitability
Medical technology company Getinge announced its second-quarter results, showing strong organic growth, high profitability, and robust cash flow. The results were positively impacted by factors including a tariff refund and operational improvements.
GOTHENBURG, Sweden – Medical technology firm Getinge AB reported a strong second quarter for 2026, with organic sales increasing by 4.6% and order intake rising by 6.2%. The adjusted EBITA margin reached 17.6%, boosted by a tariff refund of approximately SEK 336 million and improved operational performance, including a favorable product mix, price adaptations, and productivity gains.
The Acute Care Therapies division saw sales growth across most product categories, and the positive trend for consumables in life-supporting ECLS therapy continued. The Life Science segment experienced mixed results, though the high-margin Sterile Transfer category showed double-digit growth in both orders and sales. Investment sentiment in the pharmaceutical sector remained influenced by geopolitical uncertainty.
During the quarter, Getinge introduced several new products, including a new generation in endoscopic vessel harvesting (EVH), an automated endoscope reprocessing system, and a product expanding its fluorescence imaging portfolio. Furthermore, the acquisition of Pennamed, a UK-based distributor of endoscopic consumables, strengthened the company's infection prevention offerings.
Getinge maintained its full-year forecast for 2026, expecting organic sales growth of 3-5%, despite ongoing geopolitical uncertainties. The company also opened a new innovation center in Hamburg to accelerate the development of smarter, digital perioperative workflows.